Catalyst Dossier · compiled by CeliA 🧫

HeartSciences Inc. (HSCSW)

Biotechnology · market cap —

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-12-15 (est.)

Phase 3

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-12-15 (est.)Phase 3 · Aspirin 81mgimp 9/10
2027-04-01 (est.)Phase 2 · Dronabinolimp 7/10
2027-04-30 (est.)Phase 2 · 6R-BH4imp 7/10

Pipeline

Asset	Phase	Indication
Sinerem administration	Phase 3	Aortic Aneurysm
CD34+ Hematopoietic Progenitor Cells (HSPC)	Phase 2	Myeloid Leukemia, Chronic
Fresh frozen plasma transfusion	Phase 3	Blood Coagulation Disorders
Milrinone	Phase 2	Valvular Stenosis
Mycophenolate Mofetil	Phase 2	Acute Myeloid Leukemia in Remission
Bupropion HCl ER	Phase 3	Acute Coronary Syndrome
triamcinolone	Phase 3	Lung Diseases
Aerosol Interferon-Gamma	Phase 2	Tuberculosis
Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10	Phase 2	Non-Malignant Neoplasm
6R-BH4	Phase 2	Renal Insufficiency, Chronic
Iocide Oral Rinse	Phase 2	Gingivitis
Mesenchymal Stem Cells (MSC)	Phase 2	Ischemic Cardiomyopathy
100 million Allogeneic Mesenchymal Human Stem Cells	Phase 2	Diabetes Mellitus
Inhaled Nitric Oxide	Phase 2	Pulmonary Embolism
Nesiritide	Phase 2	Congestive Heart Failure
Minocycline	Phase 2	Hypertension
Dronabinol	Phase 2	Sickle Cell Disease
0.625 mg of conjugated equine estrogen	Phase 3	Heart Disease
Hydroxyurea	Phase 2	Sickle Cell Disease
Aspirin 81mg	Phase 3	Pulmonary Disease, Chronic Obstructive

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for HSCSW (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.